Modality
Small Molecule
MOA
KIF18Ai
Target
VEGF
Pathway
Cell Cycle
AsthmaObesity
Development Pipeline
Preclinical
~Aug 2011
→ ~Nov 2012
Phase 1
~Feb 2013
→ ~May 2014
Phase 2
~Aug 2014
→ ~Nov 2015
Phase 3
~Feb 2016
→ ~May 2017
NDA/BLA
Aug 2017
→ Feb 2031
NDA/BLACurrent
NCT06355384
1,281 pts·Obesity
2017-08→2031-02·Terminated
NCT06262249
1,477 pts·Asthma
2023-07→2030-02·Active
2,758 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-02-153.9y awayPh3 Readout· Asthma
2031-02-074.9y awayPh3 Readout· Obesity
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
NDA/BLA
Termina…
NDA/BLA
Active
Catalysts
Ph3 Readout
2030-02-15 · 3.9y away
Asthma
Ph3 Readout
2031-02-07 · 4.9y away
Obesity
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06355384 | NDA/BLA | Obesity | Terminated | 1281 | OS |
| NCT06262249 | NDA/BLA | Asthma | Active | 1477 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| RHH-8482 | Roche | Phase 1 | BTK | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| TAK-1836 | Takeda | Preclinical | EGFR | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| Fixaglumide | Genmab | Phase 2/3 | WEE1 |